ISSN : 1301-5680
e-ISSN : 2149-8156
Turkish Journal of Thoracic and Cardiovascular Surgery     
Investigation the effects of cilostazol and rosuvastatin on kidney and heart: An experimental acute kidney and heart injury model
Şahin İşcan1, Habib Çakır1, Fatmagül Kuşku2, İsmail Yürekli1, Borteçin Eygi1, Köksal Dönmez1, İhsan Peker1, Ali Gürbüz1
1Department of Cardiovascular Surgery, Katip Çelebi University, İzmir Atatürk Training and Researh Hospital, İzmir, Turkey
2Department of Pathology, İstanbul Bilim University, İstanbul, Turkey
DOI : 10.5606/tgkdc.dergisi.2017.13653
Background:<7b> In this study, we aimed to assess the effects of preoperative cilostazol and rosuvastatin therapy on kidney ischemia/ reperfusion injury and remote cardiac reperfusion injury in an experimental model.

Methods: A total of 35 female Sprague-Dawley rats were randomly divided into five groups (n=7). Median laparotomy and a 45-min bilateral kidney ischemia were performed. Oral medications were administered three days before the surgical intervention (20 mg/kg cilostazol, 10 mg/kg rosuvastatin and 20 mg/kg cilostazol + 10 mg/kg rosuvastatin). Blood samples and kidney and heart tissue samples were extracted one day after surgery.

Results: Immunohistochemical examination of the kidney samples revealed that tumor necrosis factor-alpha and hypoxia-inducible factor-1 alpha immunoreactivities in the cilostazol, rosuvastatin, and cilostazol + rosuvastatin groups were found to be significantly lower, compared to ischemia/reperfusion injury group (p<0.05). Immunohistochemical examination of the heart samples revealed that tumor necrosis factor-alpha immunoreactivity was significantly lower in the cilostazol group, compared to ischemia/reperfusion injury group. Hypoxia-inducible factor-1 alpha immunoreactivities were significantly lower in the cilostazol, rosuvastatin, and cilostazol + rosuvastatin groups, compared to ischemia/reperfusion injury group (p<0.05). Serum urea, creatinine, creatine kinasemuscle and brain, and troponin levels were significantly lower in the cilostazol, rosuvastatin, and cilostazol + rosuvastatin groups, compared to ischemia/reperfusion injury group (p<0.05).

Conclusion: Cilostazol and rosuvastatin have protective effects on kidney ischemia/reperfusion and remote cardiac reperfusion injury, and the protective effect can be augmented with cilostazol monotherapy, compared to combined therapy.

Keywords : Heart; ischemia/reperfusion injury; kidney
Viewed : 6246
Downloaded : 1253